Becton Dickinson & Company (BDX) Valuation

Based on the GoodMoat Target of $146.37, the current price of $158.27 implies a negative margin of safety of approximately -8.1%. According to the framework's DCF bands, this falls into the 'Unfavourable' category, as it is below the 10% threshold required for even a marginal rating. The stock's forward P/E of 25.7x is elevated compared to the broader healthcare sector and appears high relative to the company's modest 1.6% revenue growth and 6.9% ROE. This suggests the market is pricing in a significant recovery or future acceleration not yet evident in the current financials. The 5.9% FCF yield is a positive, offering some cash flow support to the valuation. When integrating this valuation assessment with the business profile, the stock appears expensive relative to its present quality indicators like growth and profitability. A value investor would typically seek a clearer margin of safety, either through a lower price or more robust growth to justify the current multiple. The neutral GoodMoat Target aligns with this assessment, indicating the stock is fairly to fully valued based on current fundamentals. Analysis based on data as of 2024-07-23.